Full access to Entrepreneur for $5
Subscribe

Why Canon (CAJ) Could Be a Top Value Stock Pick

Canon (CAJ) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions a...

By
This story originally appeared on Zacks

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?



Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Canon Inc. CAJ.

- Zacks

Canon in Focus

CAJ may be an interesting play thanks to its forward PE of 13.2, its P/S ratio of 0.8, and its decent dividend yield of 2.7%. These factors suggest that Canon is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that CAJ has decent revenue metrics to back up its earnings.

Canon, Inc. PE Ratio (TTM)

Canon, Inc. PE Ratio (TTM)

Canon, Inc. pe-ratio-ttm | Canon, Inc. Quote

But before you think that Canon is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 7.6% in the past 30 days, thanks to one upward revision in the past one month compared to none lower.



This estimate strength is actually enough to push CAJ to a Zacks Rank #1 (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.



So really, Canon is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Canon, Inc. (CAJ): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research